https://orcid.org/0000-0002-4542-4232
Research Interests
My primary research focus involves investigating novel cellular therapy and stem cell transplant strategies. My recent interests include studying how digital health technology can overcome barriers to cancer care and improve their safety, and leveraging real-world data to guide clinical decision-making.
Selected Grants
Lyell Immunopharma, Inc. / A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Therapy Product Candidate, Versus Investigator?s Choice of CD19 CAR T-Cell Therapy in Patients with Rela
Clinical TrialPrincipal Investigator · Awarded by Lyell Immunopharma, Inc. · 2026 - 2031Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2031Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease
Clinical TrialPrincipal Investigator · Awarded by Rigel Pharmaceuticals, Inc. · 2024 - 2029Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2024 - 2029Digital Multi-Vital Sign Monitoring for Early Detection of Cytokine Release Syndrome from Bispecific T-Cell Engagers and Chimeric Antigen Receptor Therapy
Clinical TrialPrincipal Investigator · Awarded by Blue Spark Technologies, Inc. · 2024 - 2029A Phase 1b/2a Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients with Diffuse Large B-cell Lymphoma Receiving CAR T-cell Therapy
Clinical TrialPrincipal Investigator · Awarded by CytoAgents, Inc. · 2024 - 2029Racial and Ethnic Differences in the Real-World Clinical Outcomes of IDH1 and IDH2 Inhibitors in Acute Myeloid Leukemia
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2024 - 2026Fellowships, Gifts & Other Supported Research
THRIVE Pre-CDA Award ·
2023
- 2023
Awarded by: Department of Veterans Affairs
Pilot Award ·
2023
- 2025
Awarded by: Leukemia & Lymphoma Society
Duke Hematology & Transfusion Medicine T32 ·
2021
- 2023
Awarded by: NIH/NHLBI
External Relationships
- Autolus
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.